The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Open accessAbstract
AIMS: Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM. METHODS AND RESULTS: Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 was a prospective, randomized, double-blind, crossover study in patients with type 2 DM and coronary artery disease (CAD). Patients (n= 35) were randomly assigned to either prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD) or clopidogrel 600 mg LD/150 mg MD over two 1-week treatment periods separated by a 2-week washout period. Platelet function was assessed by VerifyNow® P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein phosphorylation at 0, 1, 4, and 24 h and 7 days. Greater platelet inhibition by VerifyNow® P2Y12 was achieved by prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P< 0.0001; primary endpoint). The difference in platelet inhibition between prasugrel and clopidogrel was significant from 1 h through 7 days (P < 0.0001). Similar results were obtained using all other platelet function measures. Prasugrel resulted in fewer poor responders at all time points irrespective of definition used. CONCLUSION: In patients with type 2 DM and CAD, standard-dose prasugrel is associated with greater platelet inhibition and better response profiles during both the loading and maintenance periods when compared with double-dose clopidogrel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754
Self-citationPrice, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., Ernst, A., Sawhney, N. S., Schatz, R. A., & Teirstein, P. S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn046 · Cited by 651
Cited by
Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.972323 · Cited by 396
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
Ferreiro, J. L., & Angiolillo, D. J. (2011) · Circulation · doi:10.1161/circulationaha.109.913376 · Cited by 333
Self-citationBhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Self-citationAngiolillo, D. J., Jakubowski, J. A., Ferreiro, J. L., Tello-Montoliu, A., Rollini, F., Franchi, F., Ueno, M., Darlington, A., Desai, B., Moser, B. A., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1170 · Cited by 182
Self-citationHein, R., Gross, L., Aradi, D., Rieber, J., Hadamitzky, M., Merkely, B., Huczek, Z., Ince, H., Hummel, A., Baylacher, M., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-18-01077 · Cited by 12
Metadata
- Authors
- Angiolillo, D. J., Badimon, J. J., Saucedo, J. F., Frelinger, A. L., Michelson, A. D., Jakubowski, J. A., Zhu, B., Ojeh, C. K., Baker, B. A., & Effron, M. B.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-20
- Volume
- 32
- Issue
- 7
- Pages
- 838-846
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2097137681
- Cited by
- 183
- References
- 3
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehq494
- The paper
- Angiolillo, D. J., Badimon, J. J., Saucedo, J. F., Frelinger, A. L., Michelson, A. D., Jakubowski, J. A., Zhu, B., Ojeh, C. K., Baker, B. A., & Effron, M. B. (2011). A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq494
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.